Huntington disease (HD) is a dominantly inherited neurodegenerative disorder that usually presents in adulthood with characteristic motor and cognitive features and with variable and diverse psychiatric disturbances. Following the discovery of the causative defect in the HTT gene in 1993, great advances in understanding the pathogenesis of HD have been made, yet no effective disease-modifying therapy has been identified. In this new era of HD research, we have seen the emergence of a number of large clinical trials, the systematic search for novel biomarkers and the recent initiation of the first pre-manifest HD clinical studies. In this review, we seek to provide an overview of the clinical and genetic features of HD together with a summary of clinical research at this time.
Huntington G. ‘‘On Chorea.’’ Med Surg Report Phila. 1872; 26(15):317-321.
3.
Huntington’s Disease Collaborative Research Group.A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993; 72(6):971-983.
4.
Bates G., Harper P., Jones L.Huntington’s Disease. New York, NY: Oxford University Press; 2002.
5.
Pearson JS, Petersen MC, Lazarte JA, Blodgett HE, Kley IBAn educational approach to the social problem of Huntington’s chorea . Proc Staff Meet Mayo Clin. 1955;30(16):349-357.
6.
Reed TE, Chandler JH, Hughes EM, Davidson RTHuntington’s chorea in Michigan: I. Demography and genetics. Am J Hum Genet. 1958;10(2):201-225.
7.
Folstein SE, Chase GA, Wahl WE, McDonnell AM, Folstein MFHuntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet. 1987;41(2):168-179.
8.
Krause A., Temlett J., Van der Meyden K., Ross CA, Callahan C., Margolis RLCAG/CTG repeat expansions at the HDL2 locus are a common cause of Huntington disease in black South Africans. Am J Hum Genet. 2002;71:528S.
9.
Magazi DS, Krause A., Bonev V., et al. Huntington’s disease: genetic heterogeneity in black African patients. S Afr Med J. 2008;98(3):200-203.
10.
Wexler NS, Lorimer J., Porter J., et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington’s disease age of onset. Proc Natl Acad Sci U S A. 2004;101(10): 3498-3503.
11.
Warby SC, Montpetit A., Hayden AR, et al. CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup. Am J Hum Genet.2009; 84(3):351-366.
12.
Huntington Study Group.Unified Huntington’s Disease Rating Scale-99. Huntington Study Group ( 1999).
13.
Penney JB Jr , Young AB , Shoulson I., et al. Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord. 1990;5(2):93-99.
14.
Paulsen JS, Langbehn DR, Stout JC, et al. Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874-880.
15.
Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol.2009;8(9):791-801.
Nance MAHuntington disease: clinical, genetic, and social aspects. J Geriatr Psychiatry Neurol. 1998;11(2):61-70.
18.
Quinn N., Schrag A.Huntington’s disease and other choreas. J Neurol. 1998;245(11):709-716.
19.
Butters N., Wolfe J., Martone M., Granholm E., Cermak LSMemory disorders associated with Huntington’s disease: verbal recall, verbal recognition and procedural memory. Neuropsychologia . 1985;23(6):729-743.
20.
Pillon B., Dubois B., Ploska A., Agid Y.Severity and specificity of cognitive impairment in Alzheimer’s, Huntington’s, and Parkinson’s diseases and progressive supranuclear palsy. Neurology. 1991;41(5):634-643.
21.
Caine ED, Ebert MH, Weingartner H.An outline for the analysis of dementia. The memory disorder of Huntington’s disease. Neurology. 1977;27(11):1087-1092.
22.
Duff K., Paulsen JS, Beglinger LJ, Langbehn DR, Stout JC; Predict-HD Investigators of the Huntington Study Group. Psychiatric symptoms in Huntington’s disease before diagnosis: the predict-HD study . Biol Psychiatry. 2007;62(12):1341-1346.
23.
Shiwach R.Psychopathology in Huntington’s disease patients. Acta Psychiatr Scand. 1994;90(4):241-246.
24.
Craufurd D. , Thompson JC, Snowden JSBehavioral changes in Huntington Disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14(4):219-226.
25.
Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JLNeuropsychiatric aspects of Huntington’s disease. J Neurol Neurosurg Psychiatry. 2001;71(3):310-314.
26.
Schoenfeld M., Myers RH, Cupples LA, Berkman B., Sax DS, Clark E.Increased rate of suicide among patients with Huntington’s disease. J Neurol Neurosurg Psychiatry . 1984;47(12): 1283-1287.
27.
Paulsen JS, Hoth KF, Nehl C., Stierman L.Critical periods of suicide risk in Huntington’s disease. Am J Psychiatry. 2005;162(4): 725-731.
28.
Anderson KE , Gehl CR, Marder KS, Beglinger LJ, Paulsen JS; Huntington’s Study Group.Comorbidities of obsessive and compulsive symptoms in Huntington’s disease. J Nerv Ment Dis. 2010;198(5):334-338.
29.
Rosenblatt A.Neuropsychiatry of Huntington’s disease . Dialogues Clin Neurosci. 2007;9(2):191-197.
30.
Guttman M., Alpay M., Chouinard S., et al. Clinical management of psychosis and mood disorders in Huntington’s disease. In: Bédard M-A, Agid Y, Chouinard S, Fahn S, Korczyn AD, eds. Mental and Behavioral Dysfunction in Movement Disorders. Totowa, NJ: Humana; 2002:409-426.
31.
Morales LM, Estévez J., Suárez H., Villalobos R., Chacín de Bonilla L., Bonilla E.Nutritional evaluation of Huntington disease patients. Am J Clin Nutr. 1989;50(1):145-150.
32.
Pratley RE, Salbe AD, Ravussin E., Caviness JNHigher sedentary energy expenditure in patients with Huntingtons disease. Ann Neurol. 2000;47(1):64-70.
33.
Underwood BR , Broadhurst D., Dunn WB, et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain. 2006;129(4):877-886.
34.
Popovic V., Svetel M., Djurovic M., et al. Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington’s disease. Eur J Endocrinol. 2004;151(4): 451-455.
35.
Leavitt BR, Guttman JA, Hodgson JG, et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet. 2001;68(2):313-324.
36.
Van Raamsdonk JM, Murphy Z., Selva DM, et al. Testicular degeneration in Huntington disease. Neurobiol Dis. 2007;26(3): 512-520.
37.
Mastromauro CA, Meissen GJ, Cupples LA, Kiely DK, Berkman B., Myers RHEstimation of fertility and fitness in Huntington disease in New England. Am J Med Genet. 1989 ;33(2): 248-254.
38.
Hansotia P. , Wall R., Berendes J.Sleep disturbances and severity of Huntington’s disease. Neurology. 1985;35(11): 1672-1674.
39.
Morton AJ, Wood NI, Hastings MH, Hurelbrink C., Barker RA, Maywood ESDisintegration of the sleep-wake cycle and circadian timing in Huntington’s disease. J Neurosci. 2005;25(1):157-163.
40.
Petersén A., Gil J., Maat-Schieman ML, et al. Orexin loss in Huntington’s disease. Hum Mol Genet. 2005;14(1):39-47.
41.
Dennhardt J. , LeDoux MSHuntington disease in a nonagenarian mistakenly diagnosed as normal pressure hydrocephalus. J Clin Neurosci.2010;17(8):1066-1067.
42.
Nance MA, Sanders G.Characteristics of individuals with Huntington disease in long-term care. Mov Disord. 1996;11(5):542-548.
43.
National Huntington Disease Research Roster.Statistics, May 1998. Indianapolis, IN: Indiana University; 1998.
44.
Nance MA, Myers RHJuvenile onset Huntington’s disease- clinical and research perspectives . Ment Retard Dev Disabil Res Rev. 2001;7(3):153-157.
45.
Gonzalez-Alegre P., Afifi AKClinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature . J Child Neurol. 2006; 21(3):223-229.
46.
Merritt AD, Conneally PM, Rahman NF, Drew ALJuvenile Huntington’s chorea. In: Barbeau A, Brunette TR, eds. Progress in Neurogenetics. vol.1. Amsterdam, The Netherlands: Excerpta Medica; 1969:645-650.
47.
Yoon G., Kramer J., Zanko A., et al. Speech and language delay are early manifestations of juvenile-onset Huntington disease. Neurology. 2006;67(7):1265-1267.
48.
Osborne JP, Munson P., Burman D.Huntington’s chorea: report of 3 cases and review of the literature . Arch Dis Child. 1982;57(2): 99-103.
49.
Aicardi J.Diseases of the Nervous System in Childhood. London, England: Mac Keith Press; 1992:532-535.
50.
Seneca S., Fagnart D., Keymolen K., et al. Early onset Huntington disease: a neuronal degeneration syndrome . Eur J Pediatr. 2004;163(12):717-721.
51.
Nance MAGenetic testing of children at risk for Huntington’s disease. US Huntington Disease Genetic Testing Group. Neurology. 1997 ;49(4):1048-1053.
52.
Weiner W., Lang A.Movement Disorders: A Comprehensive Survey. New York, NY : Futura Publishing Company; 1989 .
53.
Squitieri F. , Pustorino G., Cannella M., et al. Highly disabling, cerebellar, juvenile-onset Huntington disease. Eur J Neurol. 2003;10(4):443-444.
Menkes JHHuntington disease: finding the gene and after. Pediatr Neurol . 1988;4(2):73-78.
56.
Brett EM, ed. Spinocerebellar degeneration and some related conditions. In: Paediatric Neurology . 2nd ed. London, England: Churchill Livingstone; 1991:223-262.
57.
Myers RH, Sax DS, Schoenfeld M., et al. Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry. 1985;48(6):530-534.
58.
Warren JD, Firgaira F., Thompson EM, Kneebone CS, Blumbergs PC, Thompson PDThe causes of sporadic and ‘senile’ chorea. Aust N Z J Med. 1998;28(4):429-431.
59.
Britton JW, Uitti RJ, Ahlskog JE, Robinson RG, Kremer B., Hayden MRHereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington’s disease. Neurology. 1995;45(3 pt 1):443-447.
60.
Cattaneo E. , Rigamonti D., Goffredo D., Zuccato C., Squitieri F., Sipione S.Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci. 2001;24(3): 182-188.
61.
Langbehn DR , Brinkman RR, Falush D., Paulsen JS, Hayden MR; International Huntington’s Disease Collaborative Group.A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet. 2004;65(4): 267-277.
62.
Langbehn DR , Hayden MR, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet.2010;153B(2):397-408.
63.
Nance M.Clinical aspects of CAG repeat disease. Brain Pathol. 1997;7(3):891-900.
64.
Rubinsztein DC, Leggo J., Coles R., et al. Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats . Am J Hum Genet. 1996;59(1):16-22.
65.
Li JL, Hayden MR, Warby SC, et al. Genome-wide significance for a modifier of age at neurological onset in Huntington’s disease at 6q23-24: the HD MAPS study. BMC Med Genet. 2006;7:71.
66.
Djousse L., Knowlton B., Hayden MR, et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics. 2004 ;5(2):109-114.
67.
Semaka A., Creighton S., Warby S., Hayden MRPredictive testing for Huntington disease: interpretation and significance of intermediate alleles. Clin Genet. 2006;70(4):283-292.
68.
Stevens D., Parsonage M.Mutation in Huntington’s chorea. J Neurol Neurosurg Psychiatry. 1969;32(2):140-143.
Mann DM, Oliver R., Snowden JSThe topographic distribution of brain atrophy in Huntington’s disease and progressive supranuclear palsy. Acta Neuropathol. 1993;85(5):553-559.
Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B.Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology. 2005;65(5): 745-747.
73.
Paulsen JS, Nopoulos PC, Aylward E., et al. Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull.2010 ;82(3-4):201-207.
74.
Henley SM, Wild EJ, Hobbs NZ, et al. Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease. J Neurol.2009;256(2):203-212.
75.
Kowall NW, Ferrante RJ, Beal MF, et al. Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study. Neuroscience. 1987;20(3):817-828.
76.
Reiner A., Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young ABDifferential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988;85(15): 5733-5737.
77.
Albin RL, Young AB, Penney JB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease. N Engl J Med. 1990; 322(18):1293-1298.
78.
Richfield EK , Maguire-Zeiss KA, Cox C., Gilmore J., Voorn P.Reduced expression of preproenkephalin in striatal neurons from Huntington’s disease patients. Ann Neurol. 1995;37(3): 335-343.
79.
Sapp E., Ge P., Aizawa H., et al. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington’s disease using high resolution image analysis. Neuroscience. 1995;64(2):397-404.
80.
Ferrante RJ , Kowall NW, Beal MF, Richardson EP Jr, Bird ED, Martin JBSelective sparing of a class of striatal neurons in Huntington’s disease. Science. 1985 ;230(4725):561-563.
81.
Dawbarn D., De Quidt ME, Emson PCSurvival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington’s disease. Brain Res. 1985;340(2):251-260.
82.
Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP Jr.Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington’s disease. J Neuropathol Exp Neurol . 1987;46(1):12-27.
83.
Davies SW, Turmaine M., Cozens BA, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 1997;90(3):537-548.
84.
Saudou F., Finkbeiner S., Devys D., Greenberg MEHuntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell. 1998;95(1): 55-66.
85.
Arrasate M. , Mitra S., Schweitzer ES, Segal MR, Finkbeiner S.Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431(7010):805-810.
86.
Aronin N., Kim M., Laforet G., DiFiglia M.Are there multiple pathways in the pathogenesis of Huntington’s disease ? Philos Trans R Soc Lond B Biol Sci. 1999 ;354(1386):995-1003.
87.
Cha JH, Frey AS, Alsdorf SA, et al. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington’s disease. Philos Trans R Soc Lond B Biol Sci. 1999;354(1386): 981-989.
88.
Cha JHTranscriptional dysregulation in Huntington’s disease. Trends Neurosci. 2000;23(9):387-392.
89.
Luthi-Carter R., Strand A., Peters NL, et al. Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease. Hum Mol Genet. 2000;9(9):1259-1271.
90.
Zucker B., Luthi-Carter R., Kama JA, et al. Transcriptional dysregulation in striatal projection- and interneurons in a mouse model of Huntington’s disease: neuronal selectivity and potential neuroprotective role of HAP1. Hum Mol Genet. 2005;14(2):179-189.
91.
Trushina E. , Dyer RB, Badger JD II, et al. Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol. 2004;24(18):8195-8209.
92.
McGeer EG, McGeer PLDuplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature. 1976;263(5577):517-519.
93.
Coyle JT, Schwarcz R.Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature. 1976; 263(5574):244-246.
94.
Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JBReplication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature. 1986; 321(6066):168-171.
95.
Sanberg PR, Calderon SF, Giordano M., Tew JM, Norman ABThe quinolinic acid model of Huntington’s disease: locomotor abnormalities . Exp Neurol. 1989;105(1):45-53.
96.
Hantraye P. , Riche D., Maziere M., Isacson O.A primate model of Huntington’s disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol. 1990;108(2):91-104.
97.
Ferrante RJ , Kowall NW, Cipolloni PB, Storey E., Beal MFExcitotoxin lesions in primates as a model for Huntington’s disease: histopathologic and neurochemical characterization . Exp Neurol. 1993;119(1):46-71.
98.
Beal MF, Hyman BT, Koroshetz W.Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 1993;16(4):125-131.
99.
Greene JG, Porter RH, Eller RV, Greenamyre JTInhibition of succinate dehydrogenase by malonic acid produces an ‘‘excitotoxic’’ lesion in rat striatum. J Neurochem. 1993;61(3): 1151-1154.
Beal MFAging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol. 1995;38(3):357-366.
102.
Peschanski M., Bachoud-Lévi AC, Hantraye P.Integrating fetal neural transplants into a therapeutic strategy: the example of Huntington’s disease. Brain. 2004;127(pt 6):1219-1228.
103.
Graham RK, Pouladi MA, Joshi P., et al. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease . J Neurosci.2009;29(7):2193-2204.
104.
Zeron MM, Hansson O., Chen N., et al. Increased sensitivity to N-methyl-d-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron. 2002;33(6):849-860.
105.
Cepeda C., Ariano MA, Calvert CR, et al. NMDA receptor function in mouse models of Huntington disease . J Neurosci Res. 2001;66(4):525-539.
106.
Beal MFMitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58(4):495-505.
107.
Fernandes HB, Baimbridge KG, Church J., Hayden MR, Raymond LAMitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington’s disease. J Neurosci. 2007; 27(50):13614-13623.
108.
Panov AV, Gutekunst CA, Leavitt BR, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci. 2002;5(8):731-736.
109.
Choo YS, Johnson GV, MacDonald M., Detloff PJ, Lesort M.Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet. 2004;13(14):1407-1420.
110.
Mangiarini L., Sathasivam K., Seller M., et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996;87(3):493-506.
111.
Hodgson JG , Agopyan N., Gutekunst CA, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23(1):181-192.
112.
Slow EJ, van Raamsdonk J., Rogers D., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003;12(13):1555-1567.
113.
Goldberg YP , Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract . Nat Genet. 1996;13(4): 442-449.
114.
Graham RK, Deng Y., Slow EJ, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006;125(6):1179-1191.
115.
Brandt J., Quaid KA, Folstein SE, et al. Presymptomatic diagnosis of delayed-onset disease with linked DNA markers. The experience in Huntington’s disease. JAMA. 1989;261(21): 3108-3114.
116.
Craufurd D., Harris R.Predictive testing for Huntington’s disease. BMJ. 1989;298(6677):892.
117.
Skraastad MI, Verwest A., Bakker E., et al. Presymptomatic, prenatal, and exclusion testing for Huntington disease using seven closely linked DNA markers. Am J Med Genet . 1991;39(2):217-222.
118.
Wiggins S., Whyte P., Huggins M., et al. The psychological consequences of predictive testing for Huntington’s disease. Canadian Collaborative Study of Predictive Testing. N Engl J Med. 1992;327(20):1401-1405.
119.
Bloch M., Adam S., Wiggins S., Huggins M., Hayden MRPredictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. Am J Med Genet. 1992;42(4): 499-507.
120.
Hayden MR, Bloch M., Wiggins S.Psychological effects of predictive testing for Huntington’s disease . In: Weiner WJ, Lang AE., eds Behavioral Neurology of Movement Disorders. Advances in Neurology. 65, New York, NY: Raven Press;1995:201-210.
121.
Huggins M. , Bloch M., Wiggins S., et al. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. Am J Med Genet. 1992;42(4):508-515.
122.
Bombard Y. , Veenstra G., Friedman JM, et al. Perceptions of genetic discrimination among people at risk for Huntington’s disease: a cross sectional survey . BMJ. 2009;338:b2175.
123.
Adam S., Wiggins S., Whyte P., et al. Five year study of prenatal testing for Huntington’s disease: demand, attitudes, and psychological assessment. J Med Genet . 1993;30(7):549-556.
124.
Sermon K., Goossens V., Seneca S., et al. Preimplantation diagnosis for Huntington’s disease (HD): clinical application and analysis of the HD expansion in affected embryos . Prenat Diagn. 1998;18(13):1427-1436.
125.
Moutou C., Gardes N., Viville S.New tools for preimplantation genetic diagnosis of Huntington’s disease and their clinical applications. Eur J Hum Genet. 2004;12(12):1007-1014.
Bardien S. , Abrahams F., Soodyall H., et al. A South African mixed ancestry family with Huntington disease-like 2: clinical and genetic features. Mov Disord. 2007;22(14):2083-2089.
Santos C., Wanderley H., Vedolin L., Pena SD, Jardim L., Sequeiros J.Huntington disease-like 2: the first patient with apparent European ancestry . Clin Genet. 2008;73(5):480-485.
130.
Schneider SA, Walker RH, Bhatia KPThe Huntington’s disease-like syndromes: what to consider in patients with a negative Huntington’s disease gene test. Nat Clin Pract Neurol. 2007;3(9):517-525.
131.
Miranda M. , Cardoso F., Giovannoni G., Church A.Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry. 2004;75(2):327-328.
132.
Kobrinsky S.Chorea Gravidarum, with the report of a case . Can Med Assoc J.1934;31(1):59-61.
133.
Myers RH, Sax DS, Koroshetz WJ, et al. Factors associated with slow progression in Huntington’s disease. Arch Neurol. 1991; 48(8):800-804.
134.
Huntington Study Group.Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66(3):366-372.
135.
Mestre T., Ferreira J., Coelho MM, Rosa M., Sampaio C.Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev.2009;(3): CD006456.
136.
Cubo E., Shannon KM, Tracy D., et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67(7):1268-1271.
137.
de Tommaso M., Difruscolo O., Sciruicchio V., Specchio N., Livrea P.Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30(1):43-46.
138.
Milnerwood AJ, Gladding CM, Pouladi MA, et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron.2010;65(2):178-190.
139.
HSG research resources page.HSG Web site. http://www.huntington-study-group.org/ . Accessed 17th September, 2010.
140.
Huntington Study GroupTrend-Hd Investigators.Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol. 2008;65(12): 1582-1589.
141.
Huntington Study Group.A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57(3):397-404.
142.
Landwehrmeyer GB, Dubois B., de Yébenes JG, et al. Riluzole in Huntington’s disease: a 3-year, randomized controlled study. Ann Neurol . 2007;62(3):262-272.
143.
Kieburtz K. , McDermott MP, Voss TS, et al. A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol.2010;67(2):154-160.
144.
Stack EC, Ferrante RJHuntington’s disease: progress and potential in the field. Expert Opin Investig Drugs. 2007; 16(12):1933-1953.
145.
Huntington Study GroupPharos Investigators.At risk for Huntington’s disease. The PHAROS cohort enrolled. Arch Neurol. 2006;63(7):991-996.
146.
Klöppel S., Henley SM, Hobbs NZ, et al. Magnetic resonance imaging of Huntington’s disease: preparing for clinical trials. Neuroscience.2009;164(1):205-219.
147.
Aylward EH , Codori AM, Barta PE, Pearlson GD, Harris GJ, Brandt J.Basal ganglia volume and proximity to onset in presymptomatic Huntington disease. Arch Neurol. 1996;53(12): 1293-1296.
148.
Aylward EH, Li Q., Stine OC, et al. Longitudinal change in basal ganglia volume in patients with Huntington’s disease. Neurology. 1997 ;48(2):394-399.
149.
Rosas HD, Liu AK, Hersch S., et al. Regional and progressive thinning of the cortical ribbon in Huntington’s disease. Neurology. 2002 ;58(5):695-701.
150.
Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain. 2008;131(pt 4):1057-1068.
151.
Harms L., Meierkord H., Timm G., Pfeiffer L., Ludolph AC. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington’s disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry. 1997;62(1):27-30.
152.
Hoang TQ, Bluml S., Dubowitz DJ, et al. Quantitative proton-decoupled 31P MRS and 1H MRS in the evaluation of Huntington’s and Parkinson’s diseases. Neurology . 1998;50(4):1033-1040.
153.
Jenkins BG , Rosas HD, Chen YC, et al. 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology. 1998;50(5):1357-1365.
154.
Sánchez-Pernaute R., García-Segura JM, del BarrioAlba A., Viaño J., de Yébenes JGClinical correlation of striatal 1H MRS changes in Huntington’ disease. Neurology. 1999;53(4):806-812.
155.
Reynolds NC Jr, Prost RW, Mark LPHeterogeneity in 1H-MRS profiles of presymptomatic and early manifest Huntington’s disease. Brain Res. 2005;1031(1):82-89.
156.
Gómez-Ansón B., Alegret M., Muñoz E., Sainz A., Monte GC, Tolosa E.Decreased frontal choline and neuropsychological performance in preclinical Huntington disease. Neurology. 2007;68(12):906-910.
157.
van Oostrom JC, Sijens PE, Roos RA, Leenders KL1H magnetic resonance spectroscopy in preclinical Huntington disease. Brain Res. 2007;1168:67-71.
158.
Ruocco HH, Lopes-Cendes I., Li LM, Cendes F.Evidence of thalamic dysfunction in Huntington disease by proton magnetic resonance spectroscopy. Mov Disord. 2007;22(14): 2052-2056.
159.
Bender A., Auer DP, Merl T., et al. Creatine supplementation lowers brain glutamate levels in Huntington’s disease. J Neurol. 2005;252(1):36-41.
160.
Hersch SM, Gevorkian S., Marder K., et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology. 2006;66(2):250-252.
161.
Leoni V., Mariotti C., Tabrizi SJ, et al. Plasma 24Shydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease. Brain. 2008;131(pt 11):2851-2859.
162.
Wild E., Björkqvist M., Tabrizi SJImmune markers for Huntington’s disease? Expert Rev Neurother. 2008;8(12): 1779-1781.
163.
Björkqvist M., Wild EJ, Thiele J., et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease . J Exp Med. 2008;205(8): 1869-1877.
164.
Creatine Safety and Tolerability in Premanifest HD: PRE-CREST . Clinical trials.gov.http://clinicaltrials.gov/ct2/show/NCT00592995. Accessed 17th September, 2010.
